Lisinopril Market Report 2026

The lisinopril market size has grown strongly in recent years. It will grow from $1.87 billion in 2025 to $1.99 billion in 2026 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to increasing incidence of hypertension, widespread clinical acceptance of ace inhibitors, growing aging population, early adoption in heart failure treatment, expansion of primary healthcare access.

The lisinopril market size is expected to see strong growth in the next few years. It will grow to $2.47 billion in 2030 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to rising cardiovascular disease burden, growing demand for affordable generic drugs, increasing focus on preventive cardiac care, expansion of treatment in diabetic kidney disease, higher healthcare spending on chronic disease management. Major trends in the forecast period include rising prevalence of hypertension and cardiovascular disorders, growing reliance on ace inhibitors for first-line therapy, expansion of generic lisinopril prescriptions, increasing use in post-heart attack management, rising long-term treatment adherence in chronic care.

The increasing prevalence of cardiovascular diseases is anticipated to drive the growth of the lisinopril market in the coming years. Cardiovascular diseases (CVDs) include a variety of disorders that impact the heart and blood vessels. The rising prevalence of these diseases is influenced by factors such as population growth and aging, presence of risk factors, and inadequate implementation of proven prevention and treatment strategies. Lisinopril helps manage cardiovascular diseases primarily by lowering blood pressure and reducing stress on the heart and kidneys. It works by inhibiting the production of angiotensin II, promoting the dilation of blood vessels, decreasing blood volume, and protecting organs from damage. For example, in May 2024, the Singapore Heart Foundation (SHF), a Singapore-based non-profit organization, reported that ischemic heart diseases caused 5,302 deaths, a slight increase from 5,290 deaths in 2022. Consequently, the rising prevalence of cardiovascular diseases is fueling the growth of the lisinopril market.

The rising prevalence of hypertension is expected to drive the growth of the lisinopril market in the coming years. Hypertension, also known as high blood pressure, is a medical condition in which the force of blood against the artery walls remains consistently elevated. Factors such as an unhealthy diet, a sedentary lifestyle, aging, and chronic stress contribute to the increasing prevalence of hypertension. Lisinopril effectively manages hypertension by inhibiting the formation of angiotensin II, which relaxes blood vessels, reduces blood volume, and lowers blood pressure. For example, in March 2023, the World Health Organization, a Switzerland-based health organization, reported that approximately 1.28 billion adults aged 30-79 years worldwide had hypertension. Thus, the growing prevalence of hypertension is fueling the lisinopril market.

In January 2024, Sun Pharmaceutical Industries Limited, an India-based pharmaceutical company, acquired Taro Pharmaceutical Industries Ltd for $347.73 million. This acquisition represented Sun Pharma's effort to expand its portfolio by leveraging Taro's expertise in generic and specialty medicines, active pharmaceutical ingredients (APIs), and over-the-counter products. Taro Pharmaceutical Industries Ltd. is a US-based company that supplies lisinopril.

Major companies operating in the lisinopril market are Merck & Co. Inc., Pfizer Inc., Viatris Inc., Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, Aurobindo Pharma Ltd., Cipla Inc., Hikma Pharmaceutical Plc, Apotex Inc., Amneal Pharmaceutical Inc., Lupin Ltd., Zydus Cadila Healthcare Ltd., Hetero Ltd., Dr. Reddy’s Laboratories Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Glenmark Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Mylan Pharmaceuticals Inc., Accord Healthcare Ltd., Sandoz International GmbH.

North America was the largest region in the lisinopril market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lisinopril market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the lisinopril market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the lisinopril market by increasing costs associated with imported active pharmaceutical ingredients and bulk drug intermediates. These effects are more pronounced for branded formulations and combination products, particularly in regions such as asia-pacific and europe that depend on global pharmaceutical supply chains. Hospitals and specialty clinics face procurement cost pressures that may affect pricing and availability. However, tariffs have also supported domestic manufacturing, strengthened local generic drug production, and improved regional supply chain resilience.

The lisinopril market research report is one of a series of new reports that provides lisinopril market statistics, including lisinopril industry global market size, regional shares, competitors with a lisinopril market share, detailed lisinopril market segments, market trends and opportunities, and any further data you may need to thrive in the lisinopril industry. This lisinopril market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Lisinopril is a medication belonging to the class of angiotensin-converting enzyme (ACE) inhibitors. It works by decreasing certain chemicals that tighten blood vessels, allowing for smoother blood flow and improving the heart's efficiency in pumping blood. Lisinopril is prescribed to adults for managing congestive heart failure and to improve survival rates after a heart attack.

The main brand types include Lisinopril Zestoretic, Prinivil, Zestril, and others. Zestoretic is a medication composed of a fixed combination of two active ingredients: lisinopril, which functions as an angiotensin-converting enzyme (ACE) inhibitor, and hydrochlorothiazide, a thiazide diuretic. The various conditions treated include hypertension, heart failure, heart attack, strokes, diabetic kidney disease, and others, with multiple dosage forms such as tablets and liquids, and it is used across different population groups including children and adults. These medications are utilized by various end-users, including hospitals, specialty clinics, and others.

The lisinopril market consists of sales of prinivil, qbrelis, zestoretic, zestril and apo-lisinopril. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.